Onconase

Onconase is still currently being tested in clinical researches but it is showing strong hopes as a medication for malignant mesothelioma. For a mesothelioma patient, participating in one of these tests may be the only way to receive this drug at the moment.
Ranpirnase and P-30 protein (or Onconase) was tested originally at Columbia University in a clinical research on patients who had advanced stages of metastasizing mesothelioma. Six months was the average survival; but some lasted one or two more years.
The developer of Onconase, Alfacell Corporation, is now conducting the IIIB phase of the clinical trial which aims to compare the effects of Ranpirnase plus Doxorubicin against Doxorubicin and another chemotherapy drug in treating malignant mesothelioma.
Onconase is a ribonuclease enzyme that is found in the early embryos or eggs of the Northern Leopard Frog. These are species of the true frog family common to some parts of the USA and Canada. It is among the primary biopharmaceutical products that has reached an advanced stage of mesothelioma clinical tests and which similarly works to RNA interference.
All types of chemotherapy drugs have side effects. If you were under Onconase, you might experience hair loss, nausea and fatigue as manifestations of the side effects.
Any mesothelioma patient may find clinical trials as an effective tool for the treatment of their cancer. However, this should be extensively discussed with the attending physician so that proper advice and recommendation be in place.